Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Ovarian cancer (OC) is the most lethal of malignant gynecological cancers, and has a very poor prognosis, frequently, attributable to late diagnosis and responsiveness to chemotherapy. In spite of the technological and medical approaches over the past four decades, involving the progression of several biological markers (mRNA and proteins biomarkers), the mortality rate of OC remains a challenge due to its late diagnosis, which is expressly ascribed to low specificities and sensitivities. Consequently, there is a crucial need for novel diagnostic and prognostic markers that can advance and initiate more individualized treatment, finally increasing survival of the patients. MiRNAs are non-coding RNAs that control target genes post transcriptionally. They are included in tumorigenesis, apoptosis, proliferation, invasion, metastasis, and chemoresistance. Several studies have within the last decade demonstrated that miRNAs are dysregulated in OC and have possibilities as diagnostic and prognostic biomarkers for OC. Additionally; recent studies have also focused on miRNAs as predictors of chemotherapy sensitivities and their potential as therapeutic targets. In this review, we discuss the current data involving the accumulating evidence of the altered expression of miRNAs in OC, their role in diagnosis, prognosis, and forecast of response to therapy. Given the heterogeneity of this disease, it is likely that advances in long-term survival might be also attained by translating the recent insights of miRNAs participation in OC into new targeted therapies that will have a crucial effect on the management of ovarian cancer.
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad
A
Mahdian-Shakib
Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ruhollah
R
Dorostkar
Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mahdi
M
Tat
Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: msh.biotechnology@gmail.com.
Mohammad Sadegh
MS
Hashemzadeh
Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran.
Navid
N
Saidi
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D025202:Molecular Diagnostic Techniques; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D035683:MicroRNAs
Diagnosis; Ovarian cancer; Prognosis; miRNA